PACULit Literature Updates: Specialty Pharmacy Track PACULit Literature Updates August 2025: Specialty Pharmacy Lesson Content 0% Complete 0/14 Steps PACULit Daily Literature Update: Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses PACULit Daily Literature Update: A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis PACULit Daily Literature Update: Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age PACULit Daily Literature Update: Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials PACULit Daily Literature Update: Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA) Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial PACULit Daily Literature Update: Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials PACULit Daily Literature Update: Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study PACULit Daily Literature Update: Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study PACULit Daily Literature Update: Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups PACULit Daily Literature Update: Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe Bimekizumab Sustains Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through 3 Years SYSA1902 Biosimilar vs Reference Ustekinumab in Moderate-to-Severe Plaque Psoriasis: Phase III Results Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study Back to Course Next Lesson
